首页> 美国卫生研究院文献>other >Development of a vaginal delivery film containing EFdA a novel anti-HIV nucleoside reverse transcriptase inhibitor
【2h】

Development of a vaginal delivery film containing EFdA a novel anti-HIV nucleoside reverse transcriptase inhibitor

机译:含EFdA(一种新型抗HIV核苷逆转录酶抑制剂)的阴道分娩膜的研制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this work was to develop a fast-dissolving film formulation containing EFdA for potential use as a topical vaginal microbicide for prevention of HIV sexual transmission. Solid state compatibility approaches were used to screen commonly used polymers for formulation development. Factorial design and desirability function were used to investigate the effect of two variables, the ratio of the polymers and the concentration of selected plasticizer on four mechanical responses including tensile strength, elongation at break, toughness and elastic modulus for optimization of the film formulation. Assessments of EFdA-loaded films included physicochemical characteristics, in vitro cytotoxicity, epithelia integrity, ex vivo permeability and bioactivity test. The optimal placebo film was composed of PVA, HPMC E5 and propylene glycol (7:3:3, w/w), and its mechanical characteristics were comparable to those of VCF® film (a commercial vaginal film product). Permeability studies using human ectocervical explants showed that there was no significant difference in cumulative permeated amount of EFdA between EFdA film and free EFdA. The results of in vitro cytotoxicity and bioactivity testing showed that 50% cytotoxic concentration (CC50) was several orders of magnitude higher than 50% effective concentration (EC50) of EFdA. Furthermore, epithelial integrity study showed that EFdA-loaded film had a much lower toxicity to HEC-1A cell monolayers as compared to VCF®. Therefore, EFdA-loaded vaginal film may be considered as a promising vaginal microbicide for HIV prevention.
机译:这项工作的目的是开发一种含有EFdA的速溶薄膜制剂,可潜在地用作预防HIV性传播的局部阴道杀菌剂。固态相容性方法用于筛选常用聚合物进行配方开发。析因设计和合意函数用于研究两个变量(聚合物的比例和所选增塑剂的浓度)对四种机械响应(包括拉伸强度,断裂伸长率,韧性和弹性模量)的影响,以优化薄膜配方。加载EFdA的薄膜的评估包括理化特性,体外细胞毒性,上皮细胞完整性,离体通透性和生物活性测试。最佳安慰剂薄膜由PVA,HPMC E5和丙二醇(7:3:3,w / w)组成,其机械特性与VCF ®薄膜(商用阴道薄膜)相当产品)。使用人宫颈外植体的渗透性研究表明,EFdA薄膜和游离EFdA之间的EFdA累积渗透量没有显着差异。体外细胞毒性和生物活性测试的结果表明,50%的细胞毒性浓度(CC50)比EFdA的50%有效浓度(EC50)高出几个数量级。此外,上皮完整性研究表明,与VCF ®相比,负载EFdA的膜对HEC-1A细胞单层的毒性低得多。因此,可将装有EFdA的阴道膜视为预防HIV的有前途的阴道杀菌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号